Synthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice

• Päätekijät: Hua Wang (Tekijä), Lifeng Xiao (Tekijä), Jianguo Tao (Tekijä), Venkat Srinivasan (Tekijä), Brendan F. Boyce (Tekijä), Frank H. Ebetino (Tekijä), Babatunde O. Oyajobi (Tekijä), Robert K. Boeckman (Tekijä), Lianping Xing (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: MDPI AG, 2018-09-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Multiple myeloma (MM) is the most common cancer affecting the bone and bone marrow and remains incurable for most patients; novel therapies are therefore needed. Bortezomib (Btz) is an FDA-approved drug for the treatment of patients with MM. However, its severe side effects require a dose reduction...